Inactive Instrument

NTN Buzztime, Inc.

NTN

US6294106066

Ntn Buzztime, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019

October 30, 2019 at 04:20 pm EDT

NTN Buzztime, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was USD 4.580 million compared to USD 6.004 million a year ago. Operating loss was USD 316,000 compared to operating Income of USD 370,000 a year ago. Net loss was USD 351,000 compared to net income of USD 222,000 a year ago. Basic loss per share from continuing operations was USD 0.12 compared to basic earnings per share from continuing operations of USD 0.08 a year ago. For the nine months, total revenue was USD 14.638 million compared to USD 17.416 million a year ago. Operating loss was USD 535,000 compared to operating Income of USD 30,000 a year ago. Net loss was USD 754,000 compared to USD 311,000 a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.12 a year ago.

Latest news about NTN Buzztime, Inc.

EGames.com Holdings LLC completed the acquisition of Social entertainment, customer engagement, and advertising technology assets of NTN Buzztime, Inc..	21-03-25	CI
Brooklyn ImmunoTherapeutics LLC completed the acquisition of NTN Buzztime, Inc. in a reverse merger transaction.	21-03-24	CI
NTN Buzztime : Plans 1-for-2 Reverse Stock Split Prior to Merger; Shares Down 12% in Late Trading	21-03-23	MT
NTN Buzztime : Obtains Shareholder Approval for Brooklyn ImmunoTherapeutics Merger	21-03-16	MT
NTN Buzztime, Inc. has Changed its Name to Brooklyn ImmunoTherapeutics, Inc	21-03-15	CI
Ntn Buzztime, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-11	CI
NTN Buzztime : Earnings Flash (NTN) NTN BUZZTIME Reports Q3 Revenue $1.5M	20-11-13	MT
Ntn Buzztime, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-13	CI
EGames.com Holdings LLC entered into an asset purchase agreement to acquire Social entertainment, customer engagement, and advertising technology assets of NTN Buzztime, Inc. for $2 million.	20-09-17	CI
NTN Buzztime, Inc. announced that it expects to receive $1 million in funding from eGames.com Holdings LLC	20-09-12	CI
NTN Buzztime to Consider Options of Its Assets	20-08-14	CI
Brooklyn ImmunoTherapeutics LLC entered into the non-binding letter of intent to acquire NTN Buzztime, Inc. for approximately $170 million in a reverse merger transaction.	20-08-12	CI
Sean Gordon Provides Information to the Shareholders	20-06-05	CI
Transcript : NTN Buzztime, Inc., Q1 2020 Earnings Call, May 19, 2020	20-05-19
NTN Buzztime, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2020	20-05-19	CI
Ntn Buzztime, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-19	CI
NTN Buzztime, Inc. Announces Board Changes	20-04-03	CI
NTN Buzztime, Inc. Auditor Raises 'Going Concern' Doubt	20-03-18	CI
Transcript : NTN Buzztime, Inc., Q4 2019 Earnings Call, Mar 17, 2020	20-03-17
Ntn Buzztime, Inc. Reports Impairment Charges for the Fourth Quarter Ended on December 31, 2019	20-03-17	CI
NTN Buzztime, Inc. Appoints Allen Wolff as Chief Executive Officer and to Its Board of Directors	20-01-15	CI
Sporcle, Inc. entered into a definitive agreement to acquire Stump! Trivia business from NTN Buzztime, Inc. for $1.4 million.	20-01-13	CI
NTN Buzztime, Inc. Announces Board Changes	19-11-26	CI
NTN Buzztime, Inc. Announces Board Changes	19-11-26	CI
Transcript : NTN Buzztime, Inc., Q3 2019 Earnings Call, Oct 30, 2019	19-10-30

Chart NTN Buzztime, Inc.

Duration

Period

More charts

Company Profile

Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic, reproducible, primary, human cell-derived Interleukin-2 (IL-2) therapeutic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. In addition to IL-2, IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as an injection around lymph node beds.

Sector

Broadcasting

More about the company

Sector Television Broadcasting

	1st Jan change	Capi.
FOX CORPORATION	+11.09%	14.99B
NEXSTAR MEDIA GROUP, INC.	+10.98%	5.9B
RTL GROUP S.A.	-14.04%	4.95B
NIPPON TELEVISION HOLDINGS, INC.	+35.08%	3.41B
SUN TV NETWORK LIMITED	-7.21%	3.16B
TEGNA INC.	-0.39%	2.67B
M6 MÉTROPOLE TÉLÉVISION	+2.01%	1.81B
NINE ENTERTAINMENT CO. HOLDINGS LIMITED	-23.02%	1.63B
PT ELANG MAHKOTA TEKNOLOGI TBK	-29.49%	1.62B

Television Broadcasting